Catalent (NYSE:CTLT) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Wednesday. The brokerage presently has a $44.00 price objective on the stock. Zacks Investment Research‘s target price indicates a potential upside of 11.45% from the company’s current price.
According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “
CTLT has been the subject of a number of other research reports. Royal Bank of Canada set a $45.00 price objective on Catalent and gave the company a “buy” rating in a research note on Friday, November 16th. First Analysis upgraded Catalent from a “neutral” rating to an “outperform” rating and lowered their price objective for the company from $47.00 to $43.00 in a research note on Wednesday, November 7th. ValuEngine upgraded Catalent from a “hold” rating to a “buy” rating in a research note on Monday, November 12th. Robert W. Baird started coverage on Catalent in a research note on Thursday, November 15th. They set an “outperform” rating for the company. Finally, UBS Group started coverage on Catalent in a research note on Tuesday, October 9th. They set a “neutral” rating and a $48.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $47.33.
Shares of NYSE:CTLT traded up $0.25 during mid-day trading on Wednesday, hitting $39.48. 1,481,327 shares of the company traded hands, compared to its average volume of 1,168,029. The company has a market cap of $5.43 billion, a P/E ratio of 24.83, a PEG ratio of 2.20 and a beta of 1.66. The company has a debt-to-equity ratio of 1.44, a quick ratio of 1.61 and a current ratio of 2.05. Catalent has a 52-week low of $29.23 and a 52-week high of $46.43.
Catalent (NYSE:CTLT) last announced its earnings results on Tuesday, February 5th. The company reported $0.45 EPS for the quarter, beating the consensus estimate of $0.37 by $0.08. Catalent had a return on equity of 19.13% and a net margin of 2.65%. The business had revenue of $623.00 million for the quarter, compared to the consensus estimate of $608.38 million. During the same period last year, the business posted $0.45 EPS. The company’s revenue was up 2.8% on a year-over-year basis. Analysts predict that Catalent will post 1.65 earnings per share for the current year.
In other news, Director John J. Greisch bought 13,000 shares of the firm’s stock in a transaction dated Thursday, November 8th. The stock was bought at an average price of $37.61 per share, for a total transaction of $488,930.00. The purchase was disclosed in a document filed with the SEC, which is available at this link. 1.40% of the stock is currently owned by company insiders.
Several institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. grew its position in shares of Catalent by 9.4% in the 3rd quarter. Vanguard Group Inc. now owns 12,925,639 shares of the company’s stock worth $588,763,000 after acquiring an additional 1,110,779 shares in the last quarter. Vanguard Group Inc grew its position in shares of Catalent by 9.4% in the 3rd quarter. Vanguard Group Inc now owns 12,925,639 shares of the company’s stock worth $588,763,000 after acquiring an additional 1,110,779 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of Catalent by 7.0% in the 3rd quarter. BlackRock Inc. now owns 12,628,951 shares of the company’s stock worth $575,248,000 after purchasing an additional 822,258 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Catalent by 29.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 7,976,203 shares of the company’s stock worth $363,316,000 after purchasing an additional 1,819,020 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its holdings in shares of Catalent by 13.0% in the 3rd quarter. Janus Henderson Group PLC now owns 7,234,661 shares of the company’s stock worth $329,539,000 after purchasing an additional 833,924 shares during the last quarter. Institutional investors own 96.76% of the company’s stock.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Further Reading: How Do You Calculate Return on Equity (ROE)?
Get a free copy of the Zacks research report on Catalent (CTLT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.